1. Home
  2. LXEO

LXEO

Lexeo Therapeutics Inc.

Logo Lexeo Therapeutics Inc.

as 04-19-2024 3:32pm EST

$
-
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

Lexeo Therapeutics Inc is a a clinical-stage genetic medicines company dedicated to transforming healthcare by applying pioneering science to fundamentally change how disease is treated. Its pipeline consists of candidates targeting patient populations that place significant burden on society and are most amenable to their genetic medicine approach. The Company is focused on preclinical and clinical stage gene therapies, and specifically on hereditary and acquired diseases of high unmet need which is their only business segment.

Founded: 2017 Country:
United States
United States
Employees: N/A City: NEW YORK
Market Cap: 398.3M IPO Year: 2023
Target Price: $21.20 AVG Volume (30 days): 101.6K
Analyst Decision: Strong Buy Number of Analysts: 5
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -12.40 EPS Growth: N/A
52 Week Low/High: $9.00 - $22.33 Next Earning Date: 03-11-2024
Revenue: N/A Revenue Growth: N/A
Revenue Growth (this year): N/A Revenue Growth (next year): N/A

Share on Social Networks: